{"id":"dsp","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Palmar-plantar erythrodysesthesia"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL5095026","moleculeType":"Small molecule","molecularWeight":"419.41"},"_dailymed":{"setId":"901833f1-62eb-4273-93a4-ce20d006ffe8","title":"HONGOSAN DSP (TOLNAFTATE) KIT [DSP SKIN CARE PRODUCTS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The liposomal encapsulation of doxorubicin allows for preferential accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect, while reducing exposure to healthy tissues. This formulation approach decreases cardiotoxicity and other dose-limiting side effects associated with free doxorubicin, allowing for improved therapeutic efficacy.","oneSentence":"DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:10:03.607Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic breast cancer"},{"name":"Ovarian cancer"},{"name":"Multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06664853","phase":"PHASE3","title":"Open-Label Extension of EryDex Study IEDAT-04-2022","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-12-11","conditions":"Ataxia Telangiectasia","enrollment":101},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":"Atopic Keratoconjunctivitis","enrollment":138},{"nctId":"NCT07392749","phase":"NA","title":"Feasibility Study of Diaphragm Synchronized Pacing (DSP) Via the Left Inferior Phrenic Vein (LIPV) Approach","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-11-28","conditions":"Heart Failure","enrollment":10},{"nctId":"NCT06193200","phase":"PHASE3","title":"Evaluate the Neurological Effects of EryDex on Subjects With A-T","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2024-06-24","conditions":"Ataxia Telangiectasia","enrollment":105},{"nctId":"NCT05585411","phase":"NA","title":"PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2022-11-01","conditions":"Bradyarrhythmia, Atrioventricular Block, Left Bundle Branch Area Pacing","enrollment":450},{"nctId":"NCT04406792","phase":"NA","title":"Mobilizing Doulas to Empower Black Women in Post-partum Diabetes Prevention","status":"WITHDRAWN","sponsor":"Vanderbilt University Medical Center","startDate":"2025-01-31","conditions":"Gestational Diabetes, Type2 Diabetes","enrollment":""},{"nctId":"NCT06645236","phase":"NA","title":"DHF-20-1839-2: Clinical Performance Study Protocol for Therascreen® KRAS RGQ PCR Kit","status":"RECRUITING","sponsor":"QIAGEN Gaithersburg, Inc","startDate":"2023-12-22","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":600},{"nctId":"NCT07032064","phase":"NA","title":"Evaluation of Electrical and Hemodynamic Effects of Different Pacing Strategies in CRT Candidates","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-03","conditions":"Heart Failure, CRT and/or ICD","enrollment":28},{"nctId":"NCT05769127","phase":"NA","title":"Diabetes Prevention and Education","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2023-04-26","conditions":"Diabetes, Pre Diabetes, Fatty Liver","enrollment":""},{"nctId":"NCT05986669","phase":"","title":"Safety and Effectiveness of DSP Dental Implant Systems: Prospective Study Multicenter Involving Real-world Data","status":"RECRUITING","sponsor":"DSP Industrial Ltda","startDate":"2023-10-18","conditions":"Dental Implant","enrollment":700},{"nctId":"NCT05450783","phase":"","title":"Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2022-09-01","conditions":"Arrhythmogenic Cardiomyopathies","enrollment":80},{"nctId":"NCT04709549","phase":"NA","title":"ObeSity and Jobs in SoCioeconomically Disadvantaged CommUnities: A Randomized CLinical Precision Public HealTh Intervention --The SCULPT-Job Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-02-10","conditions":"Weight Maintenance, Weight Loss, Stress, Psychological","enrollment":45},{"nctId":"NCT03754049","phase":"PHASE2","title":"A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2019-01-21","conditions":"Osteoarthritis of the Knee","enrollment":102},{"nctId":"NCT03563053","phase":"PHASE3","title":"Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study","status":"TERMINATED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2018-06-12","conditions":"Ataxia Telangiectasia, Genetic Syndrome","enrollment":104},{"nctId":"NCT04123561","phase":"PHASE3","title":"Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2019-11-26","conditions":"Osteoarthritis of the Knee","enrollment":504},{"nctId":"NCT06523946","phase":"","title":"Pacific Islander Physical Activity Project","status":"NOT_YET_RECRUITING","sponsor":"University of Utah","startDate":"2024-08-09","conditions":"Physical Inactivity","enrollment":150},{"nctId":"NCT06446271","phase":"","title":"Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)","status":"RECRUITING","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2024-06-26","conditions":"Cardiomyopathies, Genetic Predisposition, Cardiomyopathy, Primary","enrollment":750},{"nctId":"NCT02770807","phase":"PHASE3","title":"Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2017-03-02","conditions":"Nervous System Disease, Genetic Syndrome","enrollment":176},{"nctId":"NCT04518358","phase":"NA","title":"Expert Guiding Technology to Help Individuals With Developmental Challenges Build Life and Vocational Skills","status":"COMPLETED","sponsor":"John T. Nosek","startDate":"2019-09-01","conditions":"Autism Spectrum Disorder, Intellectual Disability","enrollment":16},{"nctId":"NCT03005873","phase":"PHASE2","title":"Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2017-03-16","conditions":"Osteoarthritis of the Knee","enrollment":76},{"nctId":"NCT03508518","phase":"NA","title":"Improving Access to Psychiatric Care for Patients in Primary Care","status":"TERMINATED","sponsor":"University Hospital, Toulouse","startDate":"2018-08-28","conditions":"Mental Disorder","enrollment":151},{"nctId":"NCT05005078","phase":"PHASE2","title":"A 16-Week Study of Pirenzepine or Placebo to Treat HIV-Associated Distal Sensory Polyneuropathy in Patients With HIV","status":"COMPLETED","sponsor":"WinSanTor, Inc","startDate":"2022-02-24","conditions":"HIV Associated Polyneuropathy","enrollment":16},{"nctId":"NCT05717036","phase":"","title":"Refractix DSP and TS Meter-DSP Measurement Comparison","status":"UNKNOWN","sponsor":"Reichert, Inc.","startDate":"2023-02-13","conditions":"Healthy","enrollment":36},{"nctId":"NCT05379296","phase":"NA","title":"Healthy Hearts: Leveraging the Diabetes Prevention Program to Decrease Health Disparities in Women of Reproductive Age","status":"WITHDRAWN","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2022-01-01","conditions":"Prediabetic State, Gestational Weight Gain, Hypertension","enrollment":""},{"nctId":"NCT05395377","phase":"NA","title":"Preventing Diabetes","status":"COMPLETED","sponsor":"Geisinger Clinic","startDate":"2017-12-18","conditions":"PreDiabetes","enrollment":84},{"nctId":"NCT02803307","phase":"PHASE1, PHASE2","title":"Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2015-06","conditions":"Osteoarthritis of the Knee","enrollment":40},{"nctId":"NCT03563560","phase":"PHASE1","title":"A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2018-05-15","conditions":"Acute Myeloid Leukemia","enrollment":10},{"nctId":"NCT03093701","phase":"PHASE2","title":"TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2017-04-01","conditions":"Retinal Vein Occlusion, Macula Edema","enrollment":31},{"nctId":"NCT02006147","phase":"PHASE1, PHASE2","title":"Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2014-11","conditions":"Central Retinal Vein Occlusion With Macular Edema, Branch Retinal Vein Occlusion With Macular Edema","enrollment":14},{"nctId":"NCT05162534","phase":"","title":"Independent Predictors on Clinical Outcomes in SARS-CoV2 Patients","status":"COMPLETED","sponsor":"University Hospital of Ferrara","startDate":"2020-05-29","conditions":"COVID-19 Patients","enrollment":1800},{"nctId":"NCT04825665","phase":"NA","title":"The Effect of Two Different Types of Forces on Possible Root Resorption in Relation to Dentin Phosphoprotein Levels","status":"COMPLETED","sponsor":"Sherifa Ghaleb","startDate":"2020-03-17","conditions":"Root Resorption","enrollment":8},{"nctId":"NCT04747002","phase":"PHASE2","title":"Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine \"Dainippon Sumitomo Phama(DSP)-7888\" for Acute Myeloid Leukemia Patients.","status":"UNKNOWN","sponsor":"Osaka University","startDate":"2020-06-12","conditions":"Acute Myeloid Leukemia in Remission","enrollment":100},{"nctId":"NCT04374851","phase":"NA","title":"A Comparative Clinical Investigation of Two Hearing Instrument Digital Signal Processing","status":"COMPLETED","sponsor":"Bernafon AG","startDate":"2020-08-03","conditions":"Hearing Loss","enrollment":19},{"nctId":"NCT03382080","phase":"NA","title":"A School-based Intervention Project to Increase Completion of Upper Secondary School in Norway","status":"COMPLETED","sponsor":"University of Bergen","startDate":"2016-02-01","conditions":"Drop Out, Absence, Academic Achievement/Average Grade","enrollment":3500},{"nctId":"NCT03501420","phase":"","title":"Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-06-13","conditions":"Sjogren's Syndrome","enrollment":2223},{"nctId":"NCT03644537","phase":"NA","title":"Correlation Between Root Resorption and Dentin Sialoprotein Upon Application of Different Orthodontic Forces.","status":"UNKNOWN","sponsor":"Aya Ahmed Moursi El Faham","startDate":"2017-10-07","conditions":"Root Resorption","enrollment":27},{"nctId":"NCT02545361","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients","status":"WITHDRAWN","sponsor":"Kahr Medical","startDate":"2018-04","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT02156349","phase":"NA","title":"A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-14","conditions":"Type II Diabetes Mellitus","enrollment":558},{"nctId":"NCT02309385","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis","status":"COMPLETED","sponsor":"Aciont Inc","startDate":"2014-10","conditions":"Non-Infectious Anterior Uveitis","enrollment":44},{"nctId":"NCT02380924","phase":"PHASE1","title":"Recovery and Survival of EryDex in Non-patient Volunteers","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2015-01","conditions":"Healthy","enrollment":10},{"nctId":"NCT00826345","phase":"NA","title":"Acupuncture/Moxibustion (Acu/Moxa) for Distal Symmetric Peripheral Neuropathy (DSP) in HIV","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2009-01","conditions":"Peripheral Neuropathy, HIV, AIDS","enrollment":20},{"nctId":"NCT00486941","phase":"PHASE3","title":"Lifestyle Intervention in Primary Health Care - the Björknäs Study","status":"COMPLETED","sponsor":"Umeå University","startDate":"2003-02","conditions":"Hypertension, Type 2 Diabetes, Obesity","enrollment":151}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"COMPLETED SUICIDE"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"DIABETES MELLITUS"},{"count":1,"reaction":"FALL"},{"count":1,"reaction":"HYPOKALAEMIA"},{"count":1,"reaction":"INJECTION SITE ULCER"},{"count":1,"reaction":"OSTEOPOROTIC FRACTURE"}],"_approvalHistory":[],"publicationCount":5332,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dexamethasone Sodium Phosphate"],"phase":"marketed","status":"active","brandName":"DSP","genericName":"DSP","companyName":"Taiwan Liposome Company","companyId":"taiwan-liposome-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DSP is a liposomal doxorubicin formulation that delivers the chemotherapy agent doxorubicin within lipid nanoparticles to improve drug targeting and reduce systemic toxicity. Used for Metastatic breast cancer, Ovarian cancer, Multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}